


Subgroup	HR	95% CI	Favours		p-value for interaction
			statin use	no statin use	
Major bleeding (statin use vs non-use)					
Rivaroxaban	0.92	0.43–1.98			0.77
Enoxaparin/VKA	0.69	0.36–1.32			
Age <60 years	0.38	0.05–2.83			0.47
Age ≥60 years	0.82	0.48–1.41			
ASA use at baseline	0.50	0.20–1.29			0.28
No ASA use at baseline	0.92	0.51–1.66			
BMI <30 kg/m²	0.79	0.44–1.41			0.84
BMI ≥30 kg/m²	0.71	0.26–1.94			
CrCl <50 ml/min	0.63	0.20–2.01			0.70
CrCl ≥50 ml/min	0.81	0.46–1.41			
Cardiac disease	0.96	0.45–2.05			0.45
No cardiac disease	0.65	0.32–1.32			
Female	0.98	0.51–1.87			0.27
Male	0.57	0.26–1.24			
					